Curative Regenerative Medicines: Preparing Health Care Systems For The Coming Wave

 
• By Faraz Ali, Ted Slocomb, and Michael Werner
  
Generate a summary of this article
Listen to this article
Beta

We may be at the dawn of a new era of curative regenerative therapies, but their inherent nature may create barriers to adoption. The Alliance for Regenerative Medicine frames the opportunities and challenges for the industry, arguing that policy makers must begin to understand the ways that these therapies represent value for money.

IV1610_ARM_1200x675

Emily Whitehead was diagnosed with an aggressive form of cancer called acute lymphoblastic leukemia (ALL) at the tender age of 5 in 2010. She had relapsed twice after chemotherapy and was out of options and near death when she was treated with an experimental chimeric antigen receptor T cell (CAR-T) gene therapy at Children’s Hospital of Philadelphia (CHOP) that saved her life. Emily’s story was published on the front page of the New York Times in December 2012.

Three years later at the American Society of HematologyAnnual Meeting, pharmaceutical giant Novartis AG revealed that Emily was not...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Market Access

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

IV-MarketAccess (Premium-1): Stimulant Medications Don’t Cause Psychosis, New Study Finds

 
• By Nabil

Instead, the new study found children with more severe attention and hyperactivity issues or other mental health conditions such as anxiety were more likely to be medicated for ADHD.

[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By Nabil

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

In Search Of Rare Disease Treatments, Nonprofits Can Lead the Charge

 
• By David Wild

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By Saba Afreen

XXXXtesting